WINTER 2025 | EYEWORLD | 35
Contact
Name: email
C
The path forward will require advocacy, up-
dated reimbursement codes, and better training.
"You can't build capacity when you're trying to
convince people to do something they'll lose
money on," Dr. Rowe said.
But there is also a call for professional intro-
spection.
"Our field has become so routinized that we
sometimes forget we are still doctors. The ques-
tion we must ask ourselves is: Are we using all
of our training and expertise to truly meet our
patients where they are?" Dr. Rowe said.
"Vision decline means something to the way
[patients with mental or cognitive delays] func-
tion in life, as it does to all of us," Dr. Ledoux
said. "Perhaps because they also have these
differences, they may have a harder fall when
their vision starts to worsen. … Our role in
helping improve these people's lives is perhaps
greater. I want [ophthalmologists] to feel in-
spired to do it."
Retaine
®
MGD
®
Advanced Formula targets all three
layers of the tear film for long-lasting comfort.
Preservative-Free
Developed for MGD Patients
Lipid Active Ingredients
Positively Charged Nano-droplets
For more information or FREE Samples call
(800) 233-5469 or visit www.ocusoft.com
© 2025 OCuSOFT Inc, Rosenberg, TX 77471 USA
Retaine
®
MGD
®
Advanced Formula
Restore Balance
for MGD Patients
OPENING
DOORS
When asked about "opening doors,"
Jonathan Rubenstein, MD, EyeWorld
Cataract Editorial Board member, said he
is excited to see developments in upcoming
cell therapies in cornea, both cultured
epithelial limbal stem cells and injection
therapies of corneal endothelial cells to
treat endothelial cell deficiency.
